AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05522920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy with and without spinal cord stimulation
Description: Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.
Study NCT04049721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBO
Description: 2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
Study NCT04049721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: 20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
Study NCT04049721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: 20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
Study NCT06392789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia
Description: Receive sleep education
Study NCT06392789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive access to website content modules
Study NCT06392789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracker
Study NCT06143020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: In the ESPB group, the patients were placed in the lateral decubitus position. The ultrasound probe was located in longitudinal orientation at the level of the T4 spinous process and then placed 3 cm laterally from the midline to the side involved in the surgery. The ultrasound landmarks, T4 transverse process, and the overlying trapezius, rhomboideus, and erector spinae muscles, were identified. Under aseptic conditions, an 80-mm 21-gauge block needle was inserted in-plane at an angle of 30-40° in the cranial-to-caudal direction until the tip contacted the T4 transverse process.After the hydrodissection with 2-3 mL of isotonic saline solution confirmed the correct needle tip position, the intermixture was injected in the interfascial plane between rhomboideus major and erector spinae muscle. Local anesthetic spread in a fascial longitudinal pattern deep to the erector spinae muscle was visualized using ultrasound guidance.
Study NCT05034510 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: modification in stimulation parameters
Study NCT04728711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
Study NCT04728711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
Study NCT06380595 — intervention group
Intervention type: PROCEDURE
Intervention: Complex endovascular aortic repair (cEVAR)
Description: Complex endovascular aortic repair (cEVAR) collectively refers to the use of fenestrated/branched EVAR (f/bEVAR) or other EVAR variations allowing alternative visceral incorporation approaches, such as laser or radiofrequency (RF) fenestration or parallel endografts (snorkel, periscope, chimney or sandwich EVAR) to enable repair of perivisceral AAA (pvAAA), thoracoabdominal aortic aneurysms (TAAA), and aortic arch aneurysms.
Study NCT06392789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06392789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive sleep compression SMS conversations
Study NCT05820828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volume control
Description: Volume control in venous reservoir during extracorporeal circulation.
Study NCT05674188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset
Description: Augmented simulation of workplace-related scenarios of pre-recorded videos using the same actors
Study NCT06316336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin Hydrochloride 10 mg
Description: Alfuzosin Hydrochloride 10 mg (test durg)
Study NCT06316336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfuzosin Hydrochloride 10 mg
Description: Alfuzosin Hydrochloride 10 mg (test durg)
Study NCT06316336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xatral® XL 10 mg
Description: Xatral® XL 10 mg (reference drug)
Study NCT06316336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xatral® XL 10 mg
Description: Xatral® XL 10 mg (reference drug)
Study NCT06305273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position for face mask ventilation during induction supine
Description: Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in supine position. Participants will be crossed over to the head elevated position after the first measurement is obtained.
Study NCT06305273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head position for face mask ventilation during induction head elevated
Description: Participant to be ventilated starting 2 minutes after induction of general anesthesia via a face mask while in head elevated position. Participants will be crossed over to the supine position after the first measurement is obtained.
Study NCT05283083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
Study NCT05516628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Resection of Primary Hepatocellular Cancer Tumour.
Study NCT05516628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Atezolizumab-Bevacizumab Therapy
Description: Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following resection of hepatocellular cancer tumour.
Study NCT06468176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) neuropsychologist
Description: * CBT: at least 3 teleconsultations by the neuropsychologist (up to 1/week maximum)~* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes / week
Study NCT04948268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive messaging intervention
Description: Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
Study NCT04948268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-personalized messaging intervention
Description: Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
Study NCT04948268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Human coaching to support intervention use and engagement via telephone calls, text or email
Study NCT04948268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational links
Description: SMS messages with URLs containing brief psychoeducational information.
Study NCT04523779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Description: The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.
Study NCT04818086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
Study NCT04818086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive a placebo which is encapsulated to look the same as the intervention drug.
Study NCT04818086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-naloxone
Description: Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
Study NCT04818086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine-naloxone
Description: Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
Study NCT06435520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy
Description: Adaptive cloud-based software delivering cognitive behavioral therapy tailored to the needs of the individual patient.
Study NCT06435520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Medication Tapering
Description: A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.
Study NCT06117540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX390
Description: WX390 tablet, 1.1 mg once a day
Study NCT04575688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
Study NCT04575688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine
Description: Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
Study NCT06393985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, venetoclax and blinatumomab
Description: Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)
Study NCT05094102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnLume Imaging System
Description: for fluorescence-guided surgery with ICG dye
Study NCT05094102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Indocyanine green is a cyanine dye used in medical diagnostics
Study NCT04743206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Airway Clearance device
Description: Subjects will be using their home standard airway clearance device, VEST (High Frequency Chest Wall Oscillation VEST) for 2 weeks followed by PIAPD.
Study NCT04743206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Internal Airway Percussion device
Description: Subjects will be using the investigational device, PIAPD (Portable Internal Airway Percussion Device) for 2 weeks.
Study NCT05156203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1301 Capsules
Description: T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
Study NCT06015165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesia plan for Anes. Group
Description: For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration. Rescue opioids will be given as sufentanil 5μg/hr, depending on the time of the last intraoperative administration. NSAIDs such as flurbiprofen axetil or ibuprofen will be administered as a complementary treatment option.
Study NCT06015165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia plan for Surg. Group
Description: For Surg. Group, hydromorphone intravenous pump is set with the same analgesic formula as in Anes. Group. Routine prescriptions for rescue opioids (tramadol) and NSAIDs according to pain level recommended by the pharmacy department will be administered.
Study NCT06015165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-modal analgesia during the surgery
Description: Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
Study NCT06015165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal analgesia during the surgery
Description: Multi-modal analgesia, including intraoperative long-acting local anesthetics (ropivacaine and methylene blue), perioperative narcotic analgesics, and postoperative laxative and antibiotics. PCIA with the same analgesic formula will be applied in both groups.
Study NCT06034262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX-IP
Description: Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
Study NCT05198986 — intervention group
Intervention type: OTHER
Intervention: Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)
Description: Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
Study NCT05258396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI without injection of contrast product
Description: MRI without injection of contrast product
Study NCT05689541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mobile app intervention
Description: A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes.
Study NCT06416449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotape application
Description: In the Star Balance Test, lines are drawn on the ground. The individual stands on their dominant foot and reaches out with the tip of the contralateral foot to touch these lines, and points are recorded. For the T-Agility Test, a course is set up, and the participant is asked to complete it as quickly as possible, with time being recorded.~As implied by its name, cones are placed in a T-shape for the T-Agility Test, and the individual is required to touch the cones and return to the starting point as quickly as possible. In the Vertical Jump Test, the individual is asked to jump as high as possible against a wall-mounted ruler, and the highest point reached is recorded. The Kinesio tape used in the study is designed to reflect the characteristics of the skin and allow for approximately 55-60% elongation of its original length. These tests are first conducted without Kinesio tape and then repeated with Kinesio tape applied. Rest intervals are provided between tests.
Study NCT05050682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: PF-07304814 is an anti-viral, formulated for intravenous delivery
Study NCT05950659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orpyx Sensory Insole System
Description: The Orpyx Sensory Insoles System uses Orpyx Sensory Technology: a powered limb overload warning technology intended for monitoring physiologic parameters, such as plantar pressure, temperature, motion, and adherence, and providing real-time cues for pressure offloading
Study NCT04702789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol-brimonidine and latanoprost
Description: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Study NCT04702789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol and latanoprost
Description: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Study NCT06132308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block with 0.25% bupivacaine
Description: Peng block was performed.
Study NCT06132308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG Block with 0.25% bupivacaine
Description: Peng block was performed.
Study NCT06566716 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CleoDX ovarian cancer test
Description: A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.
Study NCT05787483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindUP group
Description: MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
Study NCT05787483 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: business as usual; regular wellness or SEL classes
Study NCT05990465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
Study NCT05990465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV20.19 CAR T cells
Description: Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
Study NCT05494736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8527
Description: MK-8527 capsule taken by mouth.
Study NCT06362889 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microneedling with CBD
Description: Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
Study NCT05535244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered by IV infusion in 21-day cycles.
Study NCT05535244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study NCT06337097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Troponin surveillance
Description: Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.
Study NCT06337097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
Study NCT05272579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Filtrate Transfer
Description: Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
Study NCT05272579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT05546385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Rebreathing Device
Description: Partial Rebreathing Device
Study NCT05546385 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham breathing device
Description: Sham breathing device